GigaGen Wins Grants from NIH for T Cell Receptor Platform and IVIG Development

SAN FRANCISCO, CA – In July 2015, GigaGen won three new Phase I grants from the National Institute of Health (NIH) SBIR program.

One grant support innovations in GigaGen’s T cell repertoire platform that pair genotype and phenotype of millions of T cell receptors (TCRs) in a blood or tumor samples. The T cell grant is a collaboration with Dr. Everett Meyer at Stanford University Medical Center, and is now proceeding to Phase II, which will involve generating the world’s largest libraries of recombinant, natively paired TCR alpha and beta proteins from natural T cell repertoires.

The other two SBIR grants support our recombinant IVIG program to produce and characterize high powered “hyperimmunes” to fight pneumococcal infections. GigaGen has now produced recombinant hyperimmune IVIg in its labs and the project is proceeding to Phase II.

CEO Dr. Johnson is the Principal Investigator for all three grants.

GigaGen Presents at Angel Capital Association Innovation Showcase

SAN DIEGO, CA — Today, GigaGen’s CEO David Johnson presented to a group of angel investors at the Innovation Showcase of the Angel Capital Association. In the presentation, Dr. Johnson outlined GigaGen’s plans to build a recombinant IVIG.

Dr. Steve Chamow Joins GigaGen As Manufacturing Lead

SAN FRANCISCO, CA — GigaGen CEO David Johnson is excited to announce that Steve Chamow, PhD, has joined GigaGen as manufacturing lead. Dr. Chamow will help GigaGen surmount the manufacturing challenges inherent in the development of a recombinant version of IVIG.


Dr. Chamow has more than 20 years of experience in biopharmaceutical product development. A principal consultant, he helps biotechnology companies to develop CMC strategies for products in development and lifecycle strategies for marketed products. Over his career, he contributed to the development of three marketed products (Avastin, Natrecor, Vectibix).


Previously, he served as Senior Vice President, CMC, at Intradigm Corporation, a private biopharmaceutical company focused on developing RNAi therapeutics (acquired by Silence Therapeutics). Prior to Intradigm, Dr. Chamow was Vice President, Process Sciences, at Genitope Corporation and at Abgenix, Inc., (acquired by Amgen) where he built the company’s process sciences department and co-led the design and construction of Abgenix’ award-winning mammalian cell production facility in Fremont, CA.


Before Abgenix, he served as Director of Biopharmaceutical Development at Scios, Inc., (acquired by J&J), and as a scientist and senior scientist in process development at Genentech, Inc. Dr. Chamow was educated at the University of California (UC Santa Cruz, B.A. in biology; UC Davis, Ph.D. in biochemistry), and completed postdoctoral training at the National Institutes of Health. Dr. Chamow is author or co-author of more than 45 scientific publications and patents and co-editor of a 1999 book entitled Antibody Fusion Proteins.

GigaGen Profiled in Nature

San Francisco — GigaGen’s experience with the NCI/NIH Lean LaunchPad program has been highlighted in an article in Nature.


GigaGen Wins Slots in Highly Competitive Startup Accelerators

SAN FRANCISCO – GigaGen CEO David Johnson announced today that the company has won slots in two highly competitive startup accelerators: the BayBIO F.A.S.T. program, and the StartX accelerator. F.A.S.T. is a 10-week program that matches GigaGen with hundreds of biotech advisers from a variety of industries, such as contract manufacturing, clinical study design, and finance. F.A.S.T is sponsored by biotech companies interested to discover the best innovators of the Bay Area, including Johnson & Johnson, Bayer, and Amgen. StartX is an educational non-profit that accelerates the development of Stanford’s top entrepreneurs through experiential education and collective intelligence. GigaGen boasts Stanford graduates CEO David Johnson (PhD Genetics), COO Carter Keller (BS engineering), Director of R&D Adam Adler (PhD Cancer Bio), and Co-Founder Everett Meyer (Professor of Medicine; MD PhD). Fewer than 5% of applicants are accepted to the StartX program.



GigaGen Wins Grants from NCI for Antibody Technology

SAN FRANCISCO, CA – GigaGen has won two Phase I grants from the National Cancer Institute’s highly competitive SBIR program. These Phase I grants support improvements in GigaGen’s technology for high-throughput genetic analysis of primary B cells. One project involves improvements to GigaGen’s antibody protein expression technology. The second project involves improvements to GigaGen’s microfluidic chip technology, which will improve throughput tenfold over the current design. CEO Dr. Johnson is the Principal Investigator for both grants.

GigaGen Participates in Inaugural NIH I-Corps Commercialization Program

WASHINGTON DC – GigaGen Inc. participated in Steve Blank’s inaugural Lean LaunchPad for the National Cancer Institute at the National Institutes of Health. The Lean LaunchPad program has been profiled in Harvard Business Review, and is now a core part of entrepreneurship programs at business schools such as Stanford GSB and Berkeley-Haas School of Business. GigaGen interviewed a record 163 customers and stakeholders to assess the viability of their preclinical recombinant gammaglobulin product. As part of the program, GigaGen’s CEO traveled to Prague, Czech Republic, for the worldwide meeting of the European Society for Immune Deficiency, where he met with dozens of physicians, nurses, and patients. GigaGen also spoke with FDA, recombinant protein producers, plasma product companies, and the Immune Deficiency Foundation.



GigaGen Wins Grant for Immune Repertoire Sequencing Technology

SAN FRANCISCO, CA – GigaGen has won a Phase II Small Business Innovation Research (SBIR) grant for $950K from the National Cancer Institute (NCI). The funds will be used to develop and commercialize molecular kits for immune repertoire sequencing.

GigaGen Presents at the 2014 BIO International Convention

SAN DIEGO, CA – GigaGen CEO David Johnson traveled to San Diego to meet with dozens of potential collaborators at big pharma and smaller biotech companies. Dr. Johnson presented a poster describing GigaGen’s technology and opportunities for collaboration. GigaGen’s participation was generously supported by a grant from the National Science Foundation.

GigaGen Invents Novel Microfluidic Chip Geometry

SAN FRANCISCO, CA – GigaGen has invented a novel microfluidic chip geometry for water-in-oil microdroplet merging. The technology is particularly useful for applications that require lysis of a cell followed by dilution with PCR amplification reagents.